Cipronat

Ciprofloxacin

Middle ear & sinus, resp, abdominal, urinary tract, small pelvis, skin & soft tissue, bone & joint infections; sepsis. Prevention & treatment of infections in patients w/ impaired immune function (including those associated w/ immunosuppressive drugs therapy & neutropenia).

IV drop infusion Adult 200-400 mg (100-200 mL) bid for 7-10 days. Chronic bronchitis in acute stage 200 mg (100 mL) once daily for 7-10 days. Acute sinusitis 200 mg (100 mL) once daily for 10 days. Community-acquired pneumonia 200 mg (100 mL) once daily-bid for 7-14 days. Non-complicated urinary infections 200 mg as single dose or 100 mg for 3 days. Complicated urinary infections 200 mg once daily for 7-10 days. Skin & soft tissue infections 100 mg once daily for 5-7 days. Non-complicated gonorrhea 100 mg bid for 1 day. Infusion time: 60 min. Severe infections, recurring infections in patient w/ cystic fibrosis, abdominal, bone & joint infections caused by Pseudomonas or Staph, peritonitis, septicemia & acute pneumonia caused by Strep pneumoniae Increased dose to 400 mg tid. Max: 1,200 mg. Renal impairment CrCl 31-60 mL/min/1.73 m² Max: 800 mg/day, <30 mL/min/1.73 m² Max: 400 mg/day. Hemodialysis 400 mg/day after hemodialysis. Peritoneal dialysis Added to dialysate (peritoneal administration): 50 mg/1 L of dialysate qid at 6-hr interval.

Hypersensitivity to ciprofloxacin & other quinolones. Concomitant use w/ tizanidine. Pregnancy & lactation. Childn.

Patients w/ pronounced cerebral atherosclerosis, cerebral circulation disorders & renal function impairment; allergic reactions; epilepsy, history of convulsion, vascular disease & organic brain lesions. Possibility of pseudomembranous colitis. Not recommended for acute tonsillitis (tonsillar quinsy). Peristalsis-inhibiting drugs. Transitory increase in transaminase & alkaline phosphatase activity or cholestatic jaundice especially in patients w/ history of liver disease. History of CNS disorders (eg, low convulsive threshold, history of convulsive fits, reduced cerebral circulation, brain structure alterations & stroke). Discontinue at any signs of tendinitis. Tendon rupture (especially heel tendon) may occur in elderly patients w/ history of glucocorticoid treatment. Avoid UV irradiation. Concomitant use w/ theophylline, methylxanthine, caffeine, duloxetine. May affect ability to drive or operate machinery. Impaired hepatic &/or renal functions.

Nausea, diarrhea, vomiting, abdominal pain, flatulence, decreased appetite, anorexia, jaundice, cholestatic jaundice, hepatitis, hepatonecrosis, oral candidosis, pancreatitis; vertigo, headaches, increased fatigability, anxiety, tremor, insomnia, nightmares, peripheral paralgesia, increased perspiration & intracranial pressure, confused consciousness, depression, hallucinations, other psychotic reaction symptoms, migraine, unconsciousness, cerebral artery thrombosis, convulsions, hyperesthesia, uncertain gait, psychosis, ataxia, tic; taste & smell disruptions, sight impairment (diplopy, change in color perception), sonitus, hearing impairment, temporary deafness, chromatopsia; tachycardia, heart rhythm disorder, arterial hypotension, apsychia, vasodilatation; leucopenia, granulocytopenia, anemia, thrombocytopenia, thrombocytosis, leucocytosis, hemolytic anemia, prothrombin index changes, agranulocytosis, pancytopenia, bone marrow function inhibition; hypoprothrombinemia, increased liver aminase & alkaline phosphatase & amylase & lipase activity, hypercreatinemia, hyperbilirubinemia, hyperglycemia; acute renal failure, renal function impairment, vag candidosis, erythruria, crystalluria, glomerulonephritis, dysuria, polyuria, urine retention, albuminuria, urethral hemorrhages, lowered renal nitrogen clearance function, interstitial nephritis, increased urine creatinine & carbamide nitrogen; itching, skin rashes, nettle rush, hydrocysts w/ hemorrhages, small scab-forming nodes, ague, maculopapular eruptions, punctuate hemorrhages (petechia), facial or laryngeal edema, shortness of breath, labored breathing, eosinophilia, increased light sensitivity, vasculitis, erythema nodosum, exudative erythema multiforme (including Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), serum disease, anaphylactoid reactions; arthralgia, arthritis, joint edema, tendon rupture, asthenia, myalgia, superinfections (candidosis, pseudomembranous colitis), facial flushing, pathologic reactions in administration sites (edema, inflammation, pain, thrombophlebitis), limb, back or chest pain, myasthenia.

Increased blood plasma conc of theophylline, tizanidine & methotrexate. May cause convulsions w/ very large doses of quinolones & NSAIDs (including ASA). Increased serum creatinine w/ cyclosporine. Intensified effect of warfarin & glibenclamide. Increased blood plasma conc w/ probenecid. Accelerated absorption w/ metoclopramide. May increase AUC & C_max of duloxetine & strong CYP450 1A2 inhibitors (eg, fluvoxamine).

Quinolones

J01MA02 - ciprofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Rx